Brahms claims licensing first for prenatal marker:
This article was originally published in Clinica
German firm Brahms says it has become the first company to license the use of the marker free beta human chorionic gonadotrophin (free betahCG) for prenatal diagnostics. The Hennigsdorf (Berlin) company has signed a licence agreement with JN Macri Technologies, an affiliate of NTD laboratories, New York. Free betahCG is one of several prenatal markers available on Brahms' fully automatic laboratory analyser, Kryptor. The licence agreement strengthens Brahms market position in this segment. Free betahCG is patented for application as a biomarker for assessing risk for foetal anomalies during early pregnancy. Brahms also provides immunoassays for other disease areas, including for the diagnosis of sepsis and infections, thyroid diseases, cancer and cardiac disease.
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.